Clinical Trial Update: Chidamide Plus DCAG for Relapsed/Refractory AML [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating chidamide in combination with DCAG for relapsed or refractory acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Chidamide (chidamide)
• DCAG

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: AML, Relapse | Phase 1, Phase 2 | Status: UNKNOWN